Literature DB >> 12477412

New technology platforms in the development of vaccines for the future.

R Glück1, I C Metcalfe.   

Abstract

The desire for improved quality of life in both industrialised and under-developed nations has led to the quest for greater understanding and subsequent prevention and treatment of diseases. Here we discuss some of the latest of modern medicine's approaches to vaccination and disease treatment. Our main subject of discussion being the novel antigen delivery systems termed immunopotentiating reconstituted influenza virosomes (IRIVs) and their use as vaccines. Particular attention is paid to the currently licensed Epaxal and Inflexal V, good examples of the improvements being made in vaccinology. Alternative uses of virosomes such as peptide delivery, cytosolic drug delivery and gene delivery are also considered, highlighting the flexibility of the IRIV formulation and method of action. The paper concludes with consideration of alternative novel approaches to vaccinology including bacterial carriers for DNA vaccines, recombinant MV vaccines and polysaccharide-protein conjugates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477412     DOI: 10.1016/s0264-410x(02)00513-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

2.  Vaccine adjuvants: Why and how.

Authors:  Dennis Christensen
Journal:  Hum Vaccin Immunother       Date:  2016-10-02       Impact factor: 3.452

Review 3.  Hepatitis A immunisation in persons not previously exposed to hepatitis A.

Authors:  Greg J Irving; John Holden; Rongrong Yang; Daniel Pope
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

4.  Current Prospects in Peptide-Based Subunit Nanovaccines.

Authors:  Prashamsa Koirala; Sahra Bashiri; Istvan Toth; Mariusz Skwarczynski
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Nanotechnology: intelligent design to treat complex disease.

Authors:  Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.580

7.  Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.

Authors:  Pedro Cecílio; Begoña Pérez-Cabezas; Laura Fernández; Javier Moreno; Eugenia Carrillo; José M Requena; Epifanio Fichera; Steven G Reed; Rhea N Coler; Shaden Kamhawi; Fabiano Oliveira; Jesus G Valenzuela; Luigi Gradoni; Reinhard Glueck; Gaurav Gupta; Anabela Cordeiro-da-Silva
Journal:  PLoS Negl Trop Dis       Date:  2017-11-27

Review 8.  Liposomal Formulations in Clinical Use: An Updated Review.

Authors:  Upendra Bulbake; Sindhu Doppalapudi; Nagavendra Kommineni; Wahid Khan
Journal:  Pharmaceutics       Date:  2017-03-27       Impact factor: 6.321

Review 9.  Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials.

Authors:  Veena Vijayan; Adityanarayan Mohapatra; Saji Uthaman; In-Kyu Park
Journal:  Pharmaceutics       Date:  2019-10-14       Impact factor: 6.321

Review 10.  The challenge of emerging and re-emerging infectious diseases.

Authors:  David M Morens; Gregory K Folkers; Anthony S Fauci
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.